Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects
- 1 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 77 (2), 223-231
- https://doi.org/10.1007/s00228-020-03004-w
Abstract
Purpose Iberdomide is a cereblon E3 ligase modulator capable of redirecting the protein degradation machinery of the cell towards the elimination of target proteins potentially driving therapeutic effects. In vitro studies demonstrated that iberdomide predominantly undergoes oxidative metabolism mediated by cytochrome P450 (CYP) 3A4/5 but had no notable inhibition or induction of CYP enzymes. Consequently, the potential of iberdomide as a victim of drug-drug interactions (DDI) was evaluated in a clinical study with healthy subjects. Methods A total of 33 males and 5 females with 19 subjects per part were enrolled. Part 1 evaluated the pharmacokinetics (PK) of iberdomide alone (0.6 mg) and when administered with the CYP3A and P-gp inhibitor itraconazole (200 mg twice daily on day 1 and 200 once daily on days 2 through 9). Part 2 evaluated the PK of iberdomide alone (0.6 mg) and with CYP3A4 inducer rifampin (600 mg QD days 1 through 13). Plasma concentrations of iberdomide and the active metabolite M12 were determined by validated liquid chromatography-tandem mass spectrometry assay. Results Coadministration of iberdomide with itraconazole increased iberdomide peak plasma concentration (C-max) 17% and area under the concentration curve (AUC) approximately 2.4-fold relative to administration of iberdomide alone. The C(max)and AUC of iberdomide were reduced by approximately 70% and 82%, respectively, when iberdomide was administered with rifampin compared with iberdomide administered alone. Exploratory assessment of metabolite M12 concentrations demonstrated that CYP3A is responsible for M12 formation. Conclusions Caution should be taken when coadministering iberdomide with strong CYP3A inhibitors. Coadministration of iberdomide with strong CYP3A inducers is not advised.Funding Information
- Bristol-Myers Squibb
This publication has 11 references indexed in Scilit:
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)Blood, 2019
- A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and AiolosJournal of Medicinal Chemistry, 2018
- SAT0225 Cereblon modulator CC-220 decreases naÏve and memory B cells and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients: exposure-response results from a phase 2A proof of concept studyPublished by BMJ ,2017
- Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogsNature Structural & Molecular Biology, 2014
- Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition StudiesClinical Pharmacology & Therapeutics, 2014
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsScience, 2014
- Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBNBritish Journal of Haematology, 2013
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEDrug Metabolism and Disposition, 2003
- Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human HepatocytesDrug Metabolism and Disposition, 2003
- Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulationEuropean Journal of Pharmaceutical Sciences, 2001